Oxaliplatin-induced lung fibrosis

 

PDF Download Permissions and Reprints

Abstract

Oxaliplatin has been approved for use as an adjuvant treatment in stage III colorectal carcinoma by the US-FDA. The majority of toxicity caused by this drug is manageable. However, rare, isolated cases of pulmonary fibrosis induced by this drug have been reported in literature. We report one such case of rapidly evolving pulmonary fibrosis following treatment with oxaliplatin.

Publication History

Article published online:
19 November 2021

© 2009. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

• References

• 1 Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-35.
• 2 Andrι T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
• 3 Andrι T, Tournigand C, Achille E, Tubiana-Mathieu N, Lledo G, Raoul Y, et al. Adjuvant treatment of colon cancer MOSAIC study′s main results. Bull Cancer 2006;93:S5-9.
• 4 Feliu J, Salud A, Escudero P, Lopez-Gσmez L, Bolaρos M, Galαn A, et al. XELOX (capecitabine plus oxaliplatin) as first line treatment for elderly patient over 70 years of age with advanced colorectal carcinoma. Br J Cancer 2006;94:969-75.
• 5 Pasetto LM, Monfardini S. Is acute dyspnea related to oxaliplatin administration? World J Gastroenterol 2006;12:5907-8.
• 6 Ramanathan RK, Clark JW, Kemeny NE, Lenz HJ, Gococo KO, Haller DG, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 2003;21:2904-11.
• 7 Garrido M, O′Brien A, Gonzαlez S, Clavero JM, Orellana E. Cryptogenetic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report. Chest 2007;132:1997-9.
• 8 Yagόe XH, Soy E, Marino BQ, Puig J, Fabregat MB, Colomer R, et al. Interstitial pneumonitis after oxaliplatin treatment in colorrectal cancer. Clin Transl Oncol 2006;8:624.
• 9 Gagnadoux F, Roiron C, Carrie E, Monnier-Cholley L, Lebeau B. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Am J Clin Oncol 2002;25:388-90.
• 10 Arιvalo Lobera S, Sagastibeltza Mariρelarena N, Elejoste Echeberrνa I, Melι Olivι M, Egaρa Otaρo L, Basterretxea Badiola L, et al. Fatal pneumonitis induced by oxaliplatin. Clin Transl Oncol 2008;10:764-7.
• 11 Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-6.
• 12 Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008;19:1720-6.
• 13 Wilcox BE, Ryu JH, Kalra S. Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases. Respir Med 2008;102:273-9.